サラセミア治療薬の世界市場レポート 2024年

サラセミア治療薬の市場規模は、今後数年間で急速に成長すると予想されています。 2028年には10.3%の年間複合成長率（CAGR）で34億米ドルに成長すると予想されます。予測期間で予想される成長は、サラセミアに対する遺伝子治療の利用可能性の増加、標的を絞った個別化医療の需要の高まり、希少疾患の治療薬開発への投資の増加、医療費の増加、と目的を達成するための世界の取り組みに起因すると考えられます。サラセミアについての意識を高めるために。予測期間における注目すべき動向には、個別化された治療計画の採用、サラセミア管理におけるデジタルヘルスソリューションの統合、治癒療法に関する調査の進歩、併用療法の開発、患者サポートプログラムの拡大が含まれます。

サラセミア市場の予想される押し上げは、研究開発（R&D）への支出の増加によってもたらされると予想されます。研究開発投資は、その製品の開発、設計、強化のために企業が割り当てるリソースとして定義され、サラセミア治療のための先進的な医薬品の製剤化におけるイノベーションを推進する可能性を秘めています。欧州製薬産業協会連盟の報告によると、欧州の医療産業は2021年に約415億ユーロ（444億7,000万米ドル）の研究開発費を投資し、2020年の396億5,000万ユーロ（424億9,000万米ドル）から増加しました。サラセミア市場の触媒です。

サラセミア治療薬市場の成長は、増加する医療費の恩恵を受ける態勢が整っています。医療、治療、予防ケアの組織的な提供を含む医療は、個人や地域社会の健康関連問題を管理する上で極めて重要な役割を果たします。医療費の急増は、サラセミアの症例に対応するための設備を備えた専門治療センターなどの臨床インフラの強化に貢献しています。たとえば、2022年の経済調査では、インドの医療への公的支出が2021年から2022年にかけてGDPの2.1％に達したことが明らかになりました。さらに、Willis Towers Watson Public Limited Companyの調査によると、医療医療費は2021年の8.2%から2022年には8.8%に上昇し、2023年には世界平均の10%までさらに増加すると予想されています。この支出はサラセミア治療薬市場を牽引することになると思われます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界のサラセミア治療薬市場の促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界のサラセミア治療薬の市場規模実績と成長、2018～2023年
• 世界のサラセミア治療薬市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界のサラセミア治療薬市場、タイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• アルファサラセミア治療薬
• ベータサラセミア治療薬
• 世界のサラセミア治療薬市場、治療タイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 鉄キレーション療法
• その他
• 世界のサラセミア治療薬市場、流通チャネル別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 病院薬局
• オンラインプロバイダー
• ドラッグストアと小売薬局

第7章 地域と国の分析

• 世界のサラセミア治療薬市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
• 世界のサラセミア治療薬市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• サラセミア治療薬市場の競合情勢
• サラセミア治療薬市場の企業プロファイル
  • Pfizer Inc.
  • Merck &Co. Inc.
  • Novartis AG
  • Sanofi SA
  • Fresenius Kabi AG

第31章 その他の大手と革新的な企業

• Bristol Myers Squibb Co.
• Fresenius SE &Co. KGaA
• GlaxoSmithKline plc
• Teva Pharmaceutical Industries Ltd.
• Lonza Group AG
• Incyte Corporation
• Chiesi Farmaceutici SpA
• Cipla Ltd.
• Panacea Biotec Ltd.
• Ionis Pharmaceuticals Inc.
• Alvogen Inc.
• Apotex Inc.
• Acceleron Pharma Inc.
• Alnylam Pharmaceuticals Inc.
• Shanghai Bioray Laboratory Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在性分析

第36章 付録

Thalassemia drugs are medications employed in the treatment of thalassemia, an inherited blood disorder characterized by the inadequate production or abnormal type of hemoglobin. Anemia results from the extensive destruction of red blood cells caused by this disorder.

The primary categories of thalassemia drugs include alpha and beta thalassemia drugs. Alpha-thalassemia drugs are medications used to address inherited blood disorders marked by a diminished or absent production of alpha-globin subunits, leading to reduced levels of otherwise fully functional hemoglobin. Treatment options include iron chelation therapy and other modalities, with distribution through various channels such as hospital pharmacies, online providers, drug stores, and retail pharmacies.

The thalassemia drugs research report is one of a series of new reports from The Business Research Company that provides thalassemia drugs market statistics, including the thalassemia drugs industry's global market size, regional shares, competitors with thalassemia drugs market share, detailed thalassemia drugs market segments, market trends and opportunities, and any further data you may need to thrive in the thalassemia drugs industry. This thalassemia drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The thalassemia drugs market size has grown rapidly in recent years. It will grow from $2.07 billion in 2023 to $2.3 billion in 2024 at a compound annual growth rate (CAGR) of 11.4%. The growth observed in the historical period can be attributed to the increasing prevalence of thalassemia, genetic predisposition, advances in healthcare infrastructure, a growing awareness of thalassemia, and enhancements in diagnostic capabilities.

The thalassemia drugs market size is expected to see rapid growth in the next few years. It will grow to $3.4 billion in 2028 at a compound annual growth rate (CAGR) of 10.3%. The anticipated growth in the forecast period can be attributed to the increasing availability of gene therapies for thalassemia, a rising demand for targeted and personalized medicine, heightened investments in the development of drugs for rare diseases, an increase in healthcare expenditure, and global initiatives aimed at raising awareness about thalassemia. Noteworthy trends in the forecast period include the adoption of personalized treatment regimens, the integration of digital health solutions in thalassemia management, the advancement of research on curative therapies, the development of combination drug therapies, and the expansion of patient support programs.

The anticipated boost in the thalassemia market is expected to come from the rising expenditure on research and development (R&D). R&D investment, defined as the resources allocated by a company for the development, design, and enhancement of its offerings, holds the potential to drive innovation in the formulation of advanced drugs for thalassemia treatment. As reported by the European Federation of Pharmaceutical Industries and Associations, European health industries invested approximately 41.5 billion euros ($44.47 billion) in R&D expenditure in 2021, marking an increase from 39.65 billion euros ($42.49 billion) in 2020. Thus, the escalating R&D expenditure is a catalyst for the thalassemia market.

The growth of the thalassemia drug market is poised to benefit from the increasing healthcare expenditure. Healthcare, encompassing the organized provision of medical services, treatments, and preventive care, plays a pivotal role in managing health-related issues for individuals and communities. A surge in healthcare expenditure contributes to enhanced clinical infrastructure, including specialized treatment centers equipped to handle thalassemia cases. For instance, the Economic Survey of 2022 revealed that India's public expenditure on healthcare reached 2.1% of GDP in 2021-22. Additionally, a survey by Willis Towers Watson Public Limited Company indicated that healthcare benefit costs rose from 8.2% in 2021 to 8.8% in 2022, with an anticipated further increase to a global average of 10% in 2023. Therefore, the upward trajectory in healthcare expenditure is set to drive the thalassemia drug market.

A prominent trend gaining momentum in the thalassemia drug market is product innovation, with major companies focusing on developing innovative products to maintain their market position. Notably, Bluebird Bio Inc., a US-based biotechnology company, received approval for Zynteglo (betibeglogene autotemcel) in August 2022 to treat beta-thalassemia. Zynteglo stands out as the first cell-based, one-time gene therapy administered in a single dose, utilizing the patient's genetically modified cells to produce functional beta-globin.

Companies in the thalassemia drug market are emphasizing product development and the production of thalassemia drugs, particularly beta-thalassemia drugs, to sustain their market presence. Beta-thalassemia, a genetic blood disorder characterized by reduced hemoglobin production, is being targeted for innovative treatments. In August 2022, Bluebird Bio Inc. introduced a groundbreaking $2.8 million beta-thalassemia drug, representing a significant advancement in cell-based gene therapy. The company's strategic approach of waiting for additional product launches suggests a comprehensive understanding of the economic aspects of its innovative treatments for beta-thalassemia.

In November 2021, Merck, a US-based multinational pharmaceutical company, successfully acquired Acceleron Pharma Inc. for an undisclosed amount. This strategic move aims to leverage Acceleron's pioneering research to enhance Merck's capabilities in reaching more patients and advancing treatments for pulmonary arterial hypertension (PAH), which includes the development of thalassemia drugs. Acceleron Pharma Inc., a US-based clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing protein therapeutics for serious and rare diseases, including advancements in thalassemia treatment.

Major companies operating in the thalassemia drugs market report are Pfizer Inc., Merck & Co. Inc., Novartis AG, Sanofi S.A., Fresenius Kabi AG, Bristol Myers Squibb Co., Fresenius SE & Co. KGaA, GlaxoSmithKline PLC, Teva Pharmaceutical Industries Ltd., Lonza Group AG, Incyte Corporation, Chiesi Farmaceutici S.p.A., Cipla Ltd., Panacea Biotec Ltd., Ionis Pharmaceuticals Inc., Alvogen Inc., Apotex Inc., Acceleron Pharma Inc., Alnylam Pharmaceuticals Inc., Shanghai Bioray Laboratory Inc., La Jolla Pharmaceutical Company, Editas Medicine Inc., Agios Pharmaceuticals Inc., Bluebird Bio Inc., Gamida Cell Ltd., CRISPR Therapeutics AG

Asia-Pacific was the largest region in the thalassemia drugs market in 2023. The regions covered in the thalassemia drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the thalassemia drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The thalassemia drug market consists of sales of luspatercept and hydroxyurea. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Thalassemia Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on thalassemia drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for thalassemia drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The thalassemia drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type: Alpha Thalassemia Drugs; Beta Thalassemia Drugs
• 2) By Treatment Type: Iron Chelation Therapy; Other Treatments
• 3) By Distribution Channel: Hospital Pharmacies; Online Providers; Drug Stores And Retail Pharmacies
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Novartis AG; Sanofi S.A.; Fresenius Kabi AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Thalassemia Drugs Market Characteristics

3. Thalassemia Drugs Market Trends And Strategies

4. Thalassemia Drugs Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Thalassemia Drugs Market Size and Growth

• 5.1. Global Thalassemia Drugs Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Thalassemia Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Thalassemia Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Thalassemia Drugs Market Segmentation

• 6.1. Global Thalassemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Alpha Thalassemia Drugs
• Beta Thalassemia Drugs
• 6.2. Global Thalassemia Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Iron Chelation Therapy
• Other Treatments
• 6.3. Global Thalassemia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacies
• Online Providers
• Drug Stores And Retail Pharmacies

7. Thalassemia Drugs Market Regional And Country Analysis

• 7.1. Global Thalassemia Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Thalassemia Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Thalassemia Drugs Market

• 8.1. Asia-Pacific Thalassemia Drugs Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Thalassemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Thalassemia Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Thalassemia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Thalassemia Drugs Market

• 9.1. China Thalassemia Drugs Market Overview
• 9.2. China Thalassemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Thalassemia Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Thalassemia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Thalassemia Drugs Market

• 10.1. India Thalassemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Thalassemia Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Thalassemia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Thalassemia Drugs Market

• 11.1. Japan Thalassemia Drugs Market Overview
• 11.2. Japan Thalassemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Thalassemia Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Thalassemia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Thalassemia Drugs Market

• 12.1. Australia Thalassemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Thalassemia Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Thalassemia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Thalassemia Drugs Market

• 13.1. Indonesia Thalassemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Thalassemia Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Thalassemia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Thalassemia Drugs Market

• 14.1. South Korea Thalassemia Drugs Market Overview
• 14.2. South Korea Thalassemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Thalassemia Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Thalassemia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Thalassemia Drugs Market

• 15.1. Western Europe Thalassemia Drugs Market Overview
• 15.2. Western Europe Thalassemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Thalassemia Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Thalassemia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Thalassemia Drugs Market

• 16.1. UK Thalassemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Thalassemia Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Thalassemia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Thalassemia Drugs Market

• 17.1. Germany Thalassemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Thalassemia Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Thalassemia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Thalassemia Drugs Market

• 18.1. France Thalassemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Thalassemia Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Thalassemia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Thalassemia Drugs Market

• 19.1. Italy Thalassemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Thalassemia Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Thalassemia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Thalassemia Drugs Market

• 20.1. Spain Thalassemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Thalassemia Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Thalassemia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Thalassemia Drugs Market

• 21.1. Eastern Europe Thalassemia Drugs Market Overview
• 21.2. Eastern Europe Thalassemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Thalassemia Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Thalassemia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Thalassemia Drugs Market

• 22.1. Russia Thalassemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Thalassemia Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Thalassemia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Thalassemia Drugs Market

• 23.1. North America Thalassemia Drugs Market Overview
• 23.2. North America Thalassemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Thalassemia Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Thalassemia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Thalassemia Drugs Market

• 24.1. USA Thalassemia Drugs Market Overview
• 24.2. USA Thalassemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Thalassemia Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Thalassemia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Thalassemia Drugs Market

• 25.1. Canada Thalassemia Drugs Market Overview
• 25.2. Canada Thalassemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Thalassemia Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Thalassemia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Thalassemia Drugs Market

• 26.1. South America Thalassemia Drugs Market Overview
• 26.2. South America Thalassemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Thalassemia Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Thalassemia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Thalassemia Drugs Market

• 27.1. Brazil Thalassemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Thalassemia Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Thalassemia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Thalassemia Drugs Market

• 28.1. Middle East Thalassemia Drugs Market Overview
• 28.2. Middle East Thalassemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Thalassemia Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Thalassemia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Thalassemia Drugs Market

• 29.1. Africa Thalassemia Drugs Market Overview
• 29.2. Africa Thalassemia Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Thalassemia Drugs Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Thalassemia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Thalassemia Drugs Market Competitive Landscape And Company Profiles

• 30.1. Thalassemia Drugs Market Competitive Landscape
• 30.2. Thalassemia Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Merck & Co. Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Novartis AG
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Sanofi S.A.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Fresenius Kabi AG
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Thalassemia Drugs Market Other Major And Innovative Companies

• 31.1. Bristol Myers Squibb Co.
• 31.2. Fresenius SE & Co. KGaA
• 31.3. GlaxoSmithKline plc
• 31.4. Teva Pharmaceutical Industries Ltd.
• 31.5. Lonza Group AG
• 31.6. Incyte Corporation
• 31.7. Chiesi Farmaceutici S.p.A.
• 31.8. Cipla Ltd.
• 31.9. Panacea Biotec Ltd.
• 31.10. Ionis Pharmaceuticals Inc.
• 31.11. Alvogen Inc.
• 31.12. Apotex Inc.
• 31.13. Acceleron Pharma Inc.
• 31.14. Alnylam Pharmaceuticals Inc.
• 31.15. Shanghai Bioray Laboratory Inc.

32. Global Thalassemia Drugs Market Competitive Benchmarking

33. Global Thalassemia Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Thalassemia Drugs Market

35. Thalassemia Drugs Market Future Outlook and Potential Analysis

• 35.1 Thalassemia Drugs Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Thalassemia Drugs Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Thalassemia Drugs Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer